AstraZeneca Rues Loss Of Drug (Seroquel IR) Exclusivity

The Guardian.uk has;
AstraZeneca Rues Loss Of Drug Exclusivity
Posted by

Julia Kollewe

Thursday 25 October 2012 07.53 EDTguardian.co.uk

Patent expiry continues to haunt AstraZeneca, Britain's second-largest drugmaker, which reported a 19% slide in third-quarter sales on Thursday.

The company said it was hurt by the loss of exclusivity for Seroquel IR, its bestselling antipsychotic treatment, as well as Atacand for high blood pressure, antibiotic Merrem, cholesterol drug Crestor in Canada and heartburn pill Nexium in Europe. Revenues fell to $6.7bn (£4.15bn) in the third quarter from $8.2bn a year ago.

New boss Pascal Soriot, who joined from Roche and suspended share buybacks on his first day in the job at the beginning of the month, said buying in new treatments would be an important way of rebuilding the pipeline. He added that the recently launched heart drug Brilinta had the potential to do far better.

Continue reading Guardian coverage here.

Thank You Guardian.uk and Ms Kollowe

The IR suffix stands for Immediate Release as opposed to the XR which stands for Extended Release.

http://www.clinicaltrials.gov/ct2/show/NCT00926393

http://lamplightersoftware.com/dsm.php

Use the following search tool to view a summary of adverse reactions experienced by patients taking psychiatric drugs, culled from Individual Safety Reports (ISRs) submitted to the FDA's Adverse Event Reporting System (MedWatch) between January of 2004 and September of 2009. 

Quetiapine		Reported By
Adverse Reaction	Cases	MD	CN	OT	PH	LW	NR
Suicidal Ideations	479	103	106	72	13	7	266
Attempted Suicides	325	142	33	86	15	7	142
Completed Suicides	300	105	21	146	57	1	39
Deaths Not From Suicide	1,274	450	95	312	38	346	869
Homicidal Ideations	31	6	2	7	1	0	19
Homicides	16	0	6	2	0	0	9
Hypomania/Mania	123	40	26	24	5	0	40
Heart Disease	473	151	42	98	23	9	303
Movement Disorders	1,561	614	258	381	82	13	508
Birth Defects	39	19	3	12	2	0	16
Premature Births	11	4	0	8	1	0	2
Prenatal/Neonatal Deaths	38	19	5	18	1	0	10